FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1964256075> ?p ?o ?g. }

• W1964256075 endingPage "105" @default.
• W1964256075 startingPage "101" @default.
• W1964256075 abstract "<h3>Purpose</h3> Radiation Therapy Oncology Group 0417 was a phase II study that explored the safety and efficacy of the addition of bevacizumab to chemoradiation therapy. The safety results have been previously reported. Herein we report the secondary efficacy endpoints of overall survival (OS), locoregional failure (LRF), para-aortic nodal failure (PAF), distant failure (DF), and disease-free survival (DFS). <h3>Methods and Materials</h3> Eligible patients with bulky Stage IB-IIIB disease were treated with once-weekly cisplatin (40 mg/m²) chemotherapy and standard pelvic radiation therapy and brachytherapy. Bevacizumab was administered at 10 mg/kg intravenously every 2 weeks for 3 cycles during chemoradiation. For OS, failure was defined as death of any cause and was measured from study entry to date of death. LRF was defined as any failure in the pelvis. PAF was defined as any para-aortic nodal failure. DF was analyzed both including and excluding PAF. DFS was measured from study entry to date of first LRF. DF was measured with or without PAF or death. OS and DFS were estimated by the Kaplan-Meier method, and LRF and DF rates were estimated by the cumulative incidence method. <h3>Results</h3> 49 eligible patients from 28 institutions were enrolled between 2006 and 2009. The median follow-up time was 3.8 years (range, 0.8-6.0 years). The surviving patients had a median follow-up time of 3.9 years (range, 2.1-6.0 years). Most patients had tumors of International Federation of Gynecology and Obstetrics Stage IIB (63%), and 80% were squamous. The 3-year OS, DFS, and LRF were 81.3% (95% confidence interval [CI], 67.2%-89.8%), 68.7% (95% CI, 53.5%-79.8%), and 23.2% (95% CI, 11%-35.4%), respectively. The PAF, DF without PAF, and DF with PAF at 3 years were 8.4% (95% CI, 0.4%-16.3%), 14.7% (95% CI, 4.5%-24.9%), and 23.1% (95% CI 11.0%-35.2%), respectively. <h3>Conclusion</h3> In this study, bevacizumab in combination with standard pelvic chemoradiation therapy for locally advanced cervical cancer showed efficacy results that are promising and may warrant further investigation." @default.
• W1964256075 created "2016-06-24" @default.
• W1964256075 creator A5011307937 @default.
• W1964256075 creator A5025234993 @default.
• W1964256075 creator A5042395174 @default.
• W1964256075 creator A5057224046 @default.
• W1964256075 creator A5057971434 @default.
• W1964256075 creator A5058254699 @default.
• W1964256075 creator A5062040958 @default.
• W1964256075 creator A5068952612 @default.
• W1964256075 creator A5091101207 @default.
• W1964256075 date "2014-01-01" @default.
• W1964256075 modified "2023-10-18" @default.
• W1964256075 title "RTOG 0417: Efficacy of Bevacizumab in Combination With Definitive Radiation Therapy and Cisplatin Chemotherapy in Untreated Patients With Locally Advanced Cervical Carcinoma" @default.
• W1964256075 cites W1935824237 @default.
• W1964256075 cites W1963669264 @default.
• W1964256075 cites W1996583541 @default.
• W1964256075 cites W2041140757 @default.
• W1964256075 cites W2088059982 @default.
• W1964256075 cites W2101927575 @default.
• W1964256075 cites W2109134893 @default.
• W1964256075 cites W2125584535 @default.
• W1964256075 cites W2134796844 @default.
• W1964256075 cites W2147215310 @default.
• W1964256075 cites W2157719711 @default.
• W1964256075 cites W2170825221 @default.
• W1964256075 cites W2314753133 @default.
• W1964256075 cites W2324392028 @default.
• W1964256075 cites W2328935341 @default.
• W1964256075 cites W4293241248 @default.
• W1964256075 doi "https://doi.org/10.1016/j.ijrobp.2013.10.022" @default.
• W1964256075 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24331655" @default.
• W1964256075 hasPublicationYear "2014" @default.
• W1964256075 type Work @default.
• W1964256075 sameAs 1964256075 @default.
• W1964256075 citedByCount "101" @default.
• W1964256075 countsByYear W19642560752014 @default.
• W1964256075 countsByYear W19642560752015 @default.
• W1964256075 countsByYear W19642560752016 @default.
• W1964256075 countsByYear W19642560752017 @default.
• W1964256075 countsByYear W19642560752018 @default.
• W1964256075 countsByYear W19642560752019 @default.
• W1964256075 countsByYear W19642560752020 @default.
• W1964256075 countsByYear W19642560752021 @default.
• W1964256075 countsByYear W19642560752022 @default.
• W1964256075 countsByYear W19642560752023 @default.
• W1964256075 crossrefType "journal-article" @default.
• W1964256075 hasAuthorship W1964256075A5011307937 @default.
• W1964256075 hasAuthorship W1964256075A5025234993 @default.
• W1964256075 hasAuthorship W1964256075A5042395174 @default.
• W1964256075 hasAuthorship W1964256075A5057224046 @default.
• W1964256075 hasAuthorship W1964256075A5057971434 @default.
• W1964256075 hasAuthorship W1964256075A5058254699 @default.
• W1964256075 hasAuthorship W1964256075A5062040958 @default.
• W1964256075 hasAuthorship W1964256075A5068952612 @default.
• W1964256075 hasAuthorship W1964256075A5091101207 @default.
• W1964256075 hasConcept C121608353 @default.
• W1964256075 hasConcept C126322002 @default.
• W1964256075 hasConcept C141071460 @default.
• W1964256075 hasConcept C143998085 @default.
• W1964256075 hasConcept C2776694085 @default.
• W1964256075 hasConcept C2777802072 @default.
• W1964256075 hasConcept C2778220009 @default.
• W1964256075 hasConcept C2911091166 @default.
• W1964256075 hasConcept C509974204 @default.
• W1964256075 hasConcept C71924100 @default.
• W1964256075 hasConcept C88879693 @default.
• W1964256075 hasConceptScore W1964256075C121608353 @default.
• W1964256075 hasConceptScore W1964256075C126322002 @default.
• W1964256075 hasConceptScore W1964256075C141071460 @default.
• W1964256075 hasConceptScore W1964256075C143998085 @default.
• W1964256075 hasConceptScore W1964256075C2776694085 @default.
• W1964256075 hasConceptScore W1964256075C2777802072 @default.
• W1964256075 hasConceptScore W1964256075C2778220009 @default.
• W1964256075 hasConceptScore W1964256075C2911091166 @default.
• W1964256075 hasConceptScore W1964256075C509974204 @default.
• W1964256075 hasConceptScore W1964256075C71924100 @default.
• W1964256075 hasConceptScore W1964256075C88879693 @default.
• W1964256075 hasIssue "1" @default.
• W1964256075 hasLocation W19642560751 @default.
• W1964256075 hasLocation W19642560752 @default.
• W1964256075 hasOpenAccess W1964256075 @default.
• W1964256075 hasPrimaryLocation W19642560751 @default.
• W1964256075 hasRelatedWork W214785663 @default.
• W1964256075 hasRelatedWork W2168923614 @default.
• W1964256075 hasRelatedWork W2328502883 @default.
• W1964256075 hasRelatedWork W2384708512 @default.
• W1964256075 hasRelatedWork W2502269149 @default.
• W1964256075 hasRelatedWork W2564597380 @default.
• W1964256075 hasRelatedWork W2590783779 @default.
• W1964256075 hasRelatedWork W2934706655 @default.
• W1964256075 hasRelatedWork W3030201060 @default.
• W1964256075 hasRelatedWork W4253632170 @default.
• W1964256075 hasVolume "88" @default.
• W1964256075 isParatext "false" @default.
• W1964256075 isRetracted "false" @default.
• W1964256075 magId "1964256075" @default.
• W1964256075 workType "article" @default.